Expression and Prognostic Value of a Novel B7-H3 (CD276) Antibody in Acute Myeloid Leukemia

Despite recent advances in immunophenotyping, the prognosis of acute myeloid leukemia (AML) is still mainly estimated using age and genetic markers. As the genetic heterogeneity of AML patients is high, flow cytometry-based classification with appropriate biomarkers can efficiently complement risk s...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2024-07, Vol.16 (13), p.2455
Main Authors: Stefańczyk, Sylwia A, Hayn, Clara, Heitmann, Jonas, Jung, Susanne, Zekri, Latifa, Märklin, Melanie
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
Antibodies
Antigens
Biomarkers
Blood
Bone marrow
Cancer
Chromatography
Classification
Cloning
Flow cytometry
Genetic markers
Immune checkpoint
Leukemia
Leukocytes
Medical prognosis
Monocytes
Mutation
Patients
Prognosis
Proteins
Software
Survival
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite recent advances in immunophenotyping, the prognosis of acute myeloid leukemia (AML) is still mainly estimated using age and genetic markers. As the genetic heterogeneity of AML patients is high, flow cytometry-based classification with appropriate biomarkers can efficiently complement risk stratification and treatment selection. An increased expression of B7-H3 (CD276), an immune checkpoint protein, has been reported and associated with poor prognosis. However, the available data are limited and heterogeneous. Here, we used a novel, proprietary murine anti-B7-H3 8H8 antibody for the flow cytometric analysis of B7-H3 expression in AML blasts from 77 patients. Our antibody reliably detected substantial B7-H3 expression in 62.3% of AML patients. B7-H3 expression was higher in the monocytic French-American-British (FAB) M5 group and in intermediate and poor risk patients according to the European Leukemia Network. Using receiver operating characteristics (ROCs), we identified a specific fluorescence intensity cut-off of 4.45 to discriminate between B7-H3 and B7-H3 expression. High B7-H3 expression was associated with shorter overall survival (OS) and progression-free survival (PFS). In conclusion, we have developed a novel B7-H3 antibody that serves as a new tool for the detection of B7-H3 expression in AML and may help to facilitate risk stratification and treatment selection in AML patients.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16132455